Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A U.S. Oncology Network (USON) retrospective study.
Ian D. Schnadig
No relevant relationships to disclose
Thomas E. Hutson
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Hsingwen Chung
No relevant relationships to disclose
Rahul Dhanda
No relevant relationships to disclose
Melissa Halm
No relevant relationships to disclose
Michael T. Forsyth
No relevant relationships to disclose
Nicholas J. Vogelzang
Consultant or Advisory Role - Algeta/Bayer; Amgen; Boehringer Ingelheim; Celgene; Clinical Care Options; Dendreon; Eisai; Genentech; GlaxoSmithKline; Johnson & Johnson/Centocor; Lilly; Novartis; Pfizer; Sanofi ; Takeda/Millennium; US Oncology; Veridex; Viamet Pharmaceuticals; Wilex
Honoraria - Clinical Care Options; Dendreon; Genentech; Johnson & Johnson/Centocor; Lilly; Novartis; Pfizer; Sanofi ; US Oncology; Veridex; Wilex
Research Funding - Algeta/Bayer; GlaxoSmithKline; Johnson & Johnson/Centocor; Novartis; Pfizer; Takeda/Millennium; Tokai; US Oncology; Veridex; Wilex